Back to Search
Start Over
Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation
- Publication Year :
- 2020
- Publisher :
- American Society of Hematology, 2020.
-
Abstract
- TO THE EDITOR: The Imatinib Suspension and Validation (ISAV) study1 is a multicenter trial of imatinib discontinuation (ID) among patients with chronic myeloid leukemia (CML) in undetectable deep molecular remission (U-DMR). After 12 months of follow-up, 48% of patients relapsed (total n = 107), with the majority of relapses occurring within the first 9 months. An inverse relationship between patient age and risk of relapse was also observed at this timepoint. Here we report the final results of ISAV after a median follow-up of 49 months, as well as the dynamics of leukemic tumor load as determined by digital polymerase chain reaction (dPCR) in nonrelapsed patients. This trial is registered at www.clinicaltrials.gov (NCT01578213). Eligible patients were 18 years and older and had CML, either in chronic or accelerated phase, with U-DMR of at least 18 months’ duration and at least...
- Subjects :
- Adult
Male
Oncology
medicine.medical_specialty
Adolescent
Immunology
Tumor burden
Antineoplastic Agents
Biochemistry
Young Adult
chronic myeloid leukemia
MED/15 - MALATTIE DEL SANGUE
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Recurrence free survival
Internal medicine
medicine
Humans
In patient
Aged
Aged, 80 and over
business.industry
Myeloid leukemia
Imatinib
clinical trial
Cell Biology
Hematology
Middle Aged
Prognosis
BCR-ABL protein
Tumor Burden
Discontinuation
Survival Rate
Withholding Treatment
Imatinib Mesylate
Female
business
Follow-Up Studies
Cohort study
medicine.drug
discontinuation
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....373ab22048a187785430319d1067b850